表紙
市場調查報告書

巨細胞病毒(HHV-5)感染疾病:開發中產品分析

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 229755
出版日期 內容資訊 英文 191 Pages
訂單完成後即時交付
價格
巨細胞病毒(HHV-5)感染疾病:開發中產品分析 Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 191 Pages
簡介

巨細胞病毒(CMV)是皰疹病毒科的一種,是由病毒所引起的傳染性疾病。CMV會藉由唾液、尿液來傳染。常見的症狀有發燒、肺炎、體重減輕、聽障、神經病變、發育障礙等。容易罹患的危險因子除了直接接觸受感染的表面及生物之外,還有免疫力不足、先天性因素等。血液檢查及尿液檢查可以診斷出。可以服藥(抗病毒藥等)來降低症狀、或改善生活習慣等。

本報告提供巨細胞病毒(HHV-5)感染疾病的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

巨細胞病毒(HHV-5)感染疾病概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12226IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2020, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 10, 9, 17, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 8, 9, 1, 8 and 3 molecules, respectively.

Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Cytomegalovirus (HHV-5) Infections - Overview
  • Cytomegalovirus (HHV-5) Infections - Therapeutics Development
  • Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment
  • Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development
  • Cytomegalovirus (HHV-5) Infections - Drug Profiles
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects
  • Cytomegalovirus (HHV-5) Infections - Discontinued Products
  • Cytomegalovirus (HHV-5) Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Abhelix LLC, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by AlloVir Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Artemis Therapeutics Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Children's National Research Institute, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Holdings Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by China Immunotech Co Ltd, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Evrys Bio, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Helocyte Biosciences Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Pharma Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Karyopharm Therapeutics Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Macrophage Therapeutics Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Moderna Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Nobelpharma Co Ltd, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Okogen Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Orgenesis Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Provention Bio Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Qurient Co Ltd, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by SL VaxiGen Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by SpyBiotech Ltd, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Stadius Biopharma LLC, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Synklino ApS, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Vichem Chemie Research Ltd, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Viramatix Sdn Bhd, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020